Last October I wrote a story in Wired about the emergence of metabolic syndrome, a close cousion of obesity and diabetes, as a medical condition. Part of that story involved the lobbying by the pharmaceutical industry to promulgate the diagnosis, especially by Sanofi Aventis, which has submitted its rimonabant drug to the FDA for treatment of metabolic syndrome. The drug has generated great attention, and some had estimated that it could be a $3 billion blockbuster for Sanofi.
But maybe not. Story today that an advisory panel recommended to the FDA that the agency reject Sanofi’s drug - which it has named Zimulti - for side-effects involving depression.
Usually the FDA follows the advisory panels recommendations, so it doesn’t look good for Sanofi. Looks like a magic bullet for obesity is still elusive.
- Your DNA, Decoded: 23andMe and Predictive Medicine
- Your Failed Blockbuster Drug Is My Nichebuster Therapy
- Personalized Medicine: Against the Odds
- Craig Venter’s Photo
- Dark Data in Action
- What’s the Science Behind Watson’s Racism?
- The World Toilet Summit
- Genetic Medicine: How Does it Play In South Dakota?
- The Fish Dilemma: Omega 3 or Mercury?
- On Health Records, I’ll Take Microsoft Over Aetna
- CDC’s MMWR
- Health Care Industry
- mental health
November 2007 M T W T F S S « Oct 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Previously on Epidemix
- November 2007 (5)
- October 2007 (10)
- September 2007 (9)
- August 2007 (10)
- July 2007 (13)
- June 2007 (10)
- May 2007 (24)
- April 2007 (11)
- March 2007 (13)